title: High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study.
abstract: The impact of different treatment modalities and prognostic factors on the clinical course of primary thyroid diffuse large B-cell lymphoma (PTDLBCL) is still the subject of research. This study was conducted to clarify these clinical aspects of this disorder. The clinical parameters of 48 patients with PTDLBCL at time of diagnosis were comparable to those of previous studies. Patients underwent either radiotherapy (RT)  ±  surgery (SX), chemotherapy (CHT) alone or in combination with local treatments (RT or SX), or SX followed by CHT and RT. A 90% complete remission (CR) rate was observed among patients who underwent combined treatment modalities (CTM), compared to 76% among the others. The 5-year progression-free survival differed significantly between both groups (p = 0.028). Poor performance status and advanced age correlated with decreased survival. PTDLBCL is a curable disease prevalent in elderly patients. Combined treatment modalities were able to induce an elevated rate of CR, improving long-term survival in younger patients. However, the outcome in elderly patients still remains unsatisfactory.
authors.affiliation: Division of Hematology, Azienda Ospedaliera S. Maurizio, Bolzano/Bozen, Italy. michael_mian@maxxisite.com
authors.forename: Michael
authors.initials: M
authors.lastname: Mian
authors.forename: Gianluca
authors.initials: G
authors.lastname: Gaidano
authors.forename: Annarita
authors.initials: A
authors.lastname: Conconi
authors.forename: Richard
authors.initials: R
authors.lastname: Tsang
authors.forename: Mary K
authors.initials: MK
authors.lastname: Gospodarowicz
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
authors.forename: Andrea
authors.initials: A
authors.lastname: Rossi
authors.forename: Elena
authors.initials: E
authors.lastname: Oldani
authors.forename: Massimo
authors.initials: M
authors.lastname: Federico
authors.forename: Stefano
authors.initials: S
authors.lastname: Luminari
authors.forename: Monica
authors.initials: M
authors.lastname: Bellei
authors.forename: Enrico M
authors.initials: EM
authors.lastname: Pogliani
authors.forename: Fausto
authors.initials: F
authors.lastname: Rossini
authors.forename: Maria Elena
authors.initials: ME
authors.lastname: Cabrera
authors.forename: Maurizio
authors.initials: M
authors.lastname: Martelli
authors.forename: Armando
authors.initials: A
authors.lastname: Lopez-Guillermo
authors.forename: Mario
authors.initials: M
authors.lastname: Busetto
authors.forename: Franco
authors.initials: F
authors.lastname: Cavalli
authors.forename: Emanuele
authors.initials: E
authors.lastname: Zucca
authors.forename: Sergio
authors.initials: S
authors.lastname: Cortelazzo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000175:diagnosis / Q000401:mortality* / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000401:mortality / Q000628:therapy; D016896:Treatment Outcome